Aurinia Pharmaceuticals’ (AUPH) Sector Perform Rating Reiterated at Royal Bank Of Canada

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “sector perform” rating reaffirmed by Royal Bank Of Canada in a research report issued on Wednesday, MarketBeat reports. They currently have a $15.00 price objective on the biotechnology company’s stock, up from their prior price objective of $9.00. Royal Bank Of Canada’s price objective indicates a potential upside of 5.12% from the stock’s current price.

Several other research firms have also recently weighed in on AUPH. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Aurinia Pharmaceuticals has an average rating of “Hold” and a consensus target price of $16.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $14.27 on Wednesday. The business’s fifty day simple moving average is $12.14 and its two-hundred day simple moving average is $10.06. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 33.19 and a beta of 1.25. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals has a 12 month low of $6.55 and a 12 month high of $16.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.07. The firm had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts anticipate that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $636,000. Hussman Strategic Advisors Inc. raised its holdings in Aurinia Pharmaceuticals by 70.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 357,000 shares of the biotechnology company’s stock valued at $3,024,000 after acquiring an additional 147,000 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $86,000. Public Employees Retirement System of Ohio bought a new stake in Aurinia Pharmaceuticals during the second quarter valued at about $282,000. Finally, GAMMA Investing LLC raised its holdings in Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,744 shares during the period. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.